The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

Background: Mucosal healing (MH) was proposed to be an ideal treatment goal for patients
with inflammatory bowel disease (IBD). Instead of endoscopy to confirm MH, biomarkers are …

Background & Aims Endoscopic and histologic remission have emerged as key therapeutic
goals in the management of inflammatory bowel diseases (IBD) that are associated with …

Mucosal healing (MH) is vital in maintaining homeostasis within the gut and protecting
against injury and infections. Multiple factors and signaling pathways contribute in a …

Crohn's disease (CD) and ulcerative colitis (UC), known as inflammatory bowel diseases
(IBD), are characterized by chronic inflammation of the gastrointestinal tract. Over the last …

Objective IBD therapies and treatments are evolving to deeper levels of remission.
Molecular measures of disease may augment current endpoints including the potential for …

Colorectal cancer (CRC) is the third most diagnosed malignancy and a major leading cause
of cancer-related deaths worldwide. Despite advances in therapeutic regimens, the number …

Background With the introduction of novel therapies for inflammatory bowel diseases
(IBD),'treattotarget'strategies are increasingly discussed to improve shortand longterm …

Current inflammatory bowel disease (IBD) treatments including non-biological, biological,
and nutritional therapies aim to achieve remission and mucosal healing. Treatment efficacy …

ABSTRACT Background Interleukin (IL)-36 signaling has been shown to be increased in
ulcerative colitis (UC). Spesolimab, a novel humanized monoclonal antibody, targets the IL …